MedAdvisor Limited AI Stock Analysis
Want to see AU:AHE full AI Analyst Report?
MedAdvisor Limited (AHE) AI Stock Analysis
MedAdvisor Limited
(ASX:AHE)
The score is primarily held down by weak financial performance—persistent losses, negative equity in recent years, and ongoing cash burn—indicating elevated fundamental risk. Technical indicators provide only limited support (some short-term momentum but a still-weak longer-term trend). Valuation does not offset the risk because profitability is negative (negative P/E) and no dividend yield is available.
MedAdvisor Limited (AHE) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 8.29M
- Dividend Yield
- ―
- Average Volume (3M)
- 403.65K
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 1.27
- Revenue Growth
- -46.09%
- EPS Growth
- 70.70%
- Country
- Australia
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
MedAdvisor Limited Business Overview & Revenue Model
Company Description
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven p...
MedAdvisor Limited Financial Statement Overview
Summary
Financial statements indicate elevated risk: revenue has been inconsistent, profitability is deeply negative with large operating losses, shareholder equity is negative in 2025–2026, and operating/free cash flow is materially negative in 2025–2026 (ongoing cash burn). Debt reduction by 2026 is a modest offset but does not overcome the weak earnings and balance sheet position.
Income Statement
18Very NegativeBalance Sheet
22NegativeCash Flow
20Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.96M | 33.96M | 62.99M | 122.11M | 97.96M | 67.75M |
| Gross Profit | -3.49M | -3.49M | 3.97M | 23.63M | 12.59M | -1.84M |
| EBITDA | -16.55M | -16.53M | -9.87M | 7.05M | -3.03M | -11.29M |
| Net Income | -19.97M | -19.97M | -60.21M | 792.13K | -11.31M | -17.35M |
Balance Sheet | ||||||
| Total Assets | 16.59M | 16.59M | 39.84M | 98.78M | 95.91M | 78.44M |
| Cash, Cash Equivalents and Short-Term Investments | 9.53M | 9.53M | 10.30M | 15.58M | 14.20M | 7.58M |
| Total Debt | 131.74K | 131.74K | 17.40M | 12.61M | 13.09M | 13.41M |
| Total Liabilities | 19.03M | 19.03M | 41.46M | 47.20M | 47.45M | 43.89M |
| Stockholders Equity | -2.44M | -2.44M | -1.62M | 51.58M | 48.46M | 34.55M |
Cash Flow | ||||||
| Free Cash Flow | -10.27M | -10.27M | -14.37M | 3.35M | -1.63M | -548.13K |
| Operating Cash Flow | -10.27M | -10.27M | -14.37M | 5.19M | -1.45M | -236.32K |
| Investing Cash Flow | 9.92M | 9.92M | -2.18M | -2.80M | -3.23M | -290.79K |
| Financing Cash Flow | 284.23K | 284.23K | 11.34M | -831.97K | 12.42M | 1.86M |
MedAdvisor Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AHE, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 44.76 is Neutral, neither overbought nor oversold. The STOCH value of -100.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AHE.
MedAdvisor Limited Peers Comparison
Overall Rating
AU:ALC63Neutral
AU:ONE51Neutral
AU:PHX45Neutral- AU:AHE44Neutral
AU:ICR40Underperform
AU:PCK38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:ALC | 63Neutral | AUD 141.73M | 65.88 | 2.53% | ― | 26.61% | 41.67% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:ONE | 51Neutral | AUD 113.29M | -6.51 | -203.69% | ― | -1.53% | 28.29% |
| AU:PHX | 45Neutral | AUD 45.47M | -17.58 | -9.39% | ― | 4.06% | -625.00% |
| AU:AHE | 44Neutral | AUD 8.29M | -0.42 | -614.15% | ― | -46.09% | 70.70% |
| AU:ICR | 40Underperform | AUD 12.88M | -5.00 | -416.53% | ― | 113.42% | 29.17% |
| AU:PCK | 38Underperform | AUD 14.65M | -1.59 | -1688.04% | ― | 11.45% | 0.69% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:AHE | MedAdvisor Limited | 0.01 | -0.01 | -45.83% | |
| AU:ONE | Oneview Healthcare PLC Chess Depository Interests repr 1 | 0.14 | -0.13 | -49.06% | |
| AU:PHX | PharmX Technologies Limited | 0.07 | -0.08 | -54.00% | |
| AU:ALC | Alcidion Group Limited | 0.12 | 0.01 | 15.00% | |
| AU:ICR | InteliCare Holdings Limited | 0.02 | -0.01 | -29.17% | |
| AU:PCK | PainChek Ltd | 0.07 | -0.38 | -83.78% |
MedAdvisor Limited Corporate Events
Mercer Ceases to Be Substantial Holder in Adheris Health
Mercer Investments (Australia) Limited, as trustee of the WSSP Australian Equities Trust, ceased to be a substantial holder in Adheris Health Limited (ASX: AHE) on 9 November 2026. The release identifies changes in relevant interests and voting secur...
Adheris Health to Release Director Shares From Voluntary Escrow in November 2026
Adheris Health Limited has advised that 1,750,000 fully paid ordinary shares will be released from voluntary escrow on 6 November 2026, followed by a further 2,000,000 shares on 26 November 2026. The shares, which are held by current and former direc...
Adheris Health posts Q1 margin uplift as it pivots to higher-growth digital pharma programs
Adheris Health reported modest year-on-year revenue and gross profit growth for Q1 FY27, with a sharp rebound versus the prior quarter driven by out-of-cycle bookings, customer win-backs and program add-ons. Gross margin improved to 45.2% on lower pl...
Adheris Health Dispatches AGM Documents and Promotes Digital Investor Communication
Adheris Health Limited has dispatched key documents for its upcoming Annual General Meeting to shareholders, including the formal meeting notice, notice of access and proxy forms, ahead of the 18 November 2026 session in Melbourne. The company is rem...
Adheris Health aligns reporting calendar and shifts to U.S. dollar reporting
Adheris Health Limited has shifted its financial year-end from 30 June to 31 December to align its reporting cycle with key U.S.-based pharmaceutical clients and their health program planning timelines. The company will operate a six‑month transition...
EBOS Exits Substantial Holding in MedAdvisor’s Adheris Health Unit
MedAdvisor’s subsidiary Adheris Health Limited is positioned in the health technology and pharmaceutical services industry, delivering digital adherence and patient engagement solutions to pharmacies, healthcare professionals and drug manufacturers....
Adheris Health Director Kate Hill Increases Direct Shareholding via Off-Market Trade
Adheris Health Limited has disclosed a change in the holdings of director Catherine (Kate) Jane Hill, who increased her direct ownership in the company through an off-market trade at a nominal price of $0.01 per share. Following the transaction, Hill...
Adheris Health Leaders Boost Stakes as Insider Buying Signals Confidence
Adheris Health has disclosed that its board and management have acquired about 27 million shares, equivalent to 4.2% of the company’s outstanding stock, while a long-term supportive shareholder has purchased an additional 27 million shares representi...
Adheris Health Issues FY26 Results Presentation with Extensive Legal Disclaimers
Adheris Health released its FY26 results presentation, framing the document as general information rather than investment advice and emphasizing that it does not account for individual investor circumstances. The company stresses that the material is...
Adheris Health appoints new CFO to support U.S. rebuild and profitability push
Adheris Health Limited has appointed Alison Hale as Chief Financial Officer, effective 1 September 2026, replacing outgoing CFO Sean Slattery. Hale brings experience from Deloitte and senior finance roles at the Linde Group and Elgas Limited, with a...
Adheris Health Cuts Costs and Stabilises Cash Flow as Revenue Slides
Adheris Health reported FY26 revenue of A$34.0 million from continuing operations, down 46% year on year, with gross profit and margins also weaker amid lower customer renewals and reduced bookings in the prior pharma budget cycle. Statutory net loss...
Adheris Health Completes Strategic Reset to Refocus on U.S. Growth
Adheris Health has completed a strategic reset over the year to 30 June 2026, upgrading its technology platform to deliver programs at scale and refreshing its executive leadership while recommitting to core customer relationships. The company has st...
Adheris Health lodges ASX governance key and updates corporate oversight framework
Adheris Health Limited has lodged its Appendix 4G and related corporate governance disclosures for the year ended 30 June 2026 with the ASX. The company has elected to host its corporate governance statement on its website, confirming board approval...
Adheris Health Sets Date for FY26 Results and Investor Webinar
Adheris Health Limited, a healthcare technology company specializing in data-driven patient engagement and medication adherence solutions for pharmaceutical manufacturers, pharmacies, and healthcare providers, operates the THRiV platform to personali...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026